A Phase 1 interventional study of MWN105 and MWN105 in Overweight , Obesity, Type 2 Diabetes Mellitus (T2DM) and MASH - Metabolic Dysfunction-Associated Steatohepatitis, sponsored by Shanghai Minwei Biotechnology Co., Ltd. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-03.
Sponsored by Shanghai Minwei Biotechnology Co., Ltd (part of Lepu Medical) · Phase 1, Interventional, and Treatment
Among 14 studies in Obesity by Shanghai Minwei Biotechnology Co., Ltd — 6 open to participants now, 8 under way, 1 of them phase 3. Obesity · Shanghai Minwei Biotechnology Co., Ltd.
Among the 14 studies in Obesity by Shanghai Minwei Biotechnology Co., Ltd, this one is the 11th largest by enrollment, is the only one that started in 2024, is one of 8 in phase 1, and was the 9th registered.
11,522 studies on the registry are indexed under Obesity; 2,033 are open to participants now.
This study's enrollment of 55 is below the median of 67 across 9,006 interventional studies indexed under Obesity.
Browse Obesity studies →6 of the 14 studies in Obesity by Shanghai Minwei Biotechnology Co., Ltd are open now, in 2 countries. Each count lists the studies.
Of the 1,336 Obesity studies recruiting now, 377 (28%) set no upper age limit and 856 (64%) stop at 75 or younger; 168 take children under 18; 491 take healthy volunteers.
This study: 18 Years to 45 Years · all sexes · healthy volunteers too.
The full table on the hub →14 studies; the count open now beside each. This study's row is marked.
First in 2024; this study’s year is marked. 1 started in 2024.
Median enrollment 88 across the 14 interventional studies. Of the 6 that completed or were terminated, 0 (0%) have results posted.
Shanghai Minwei Biotechnology Co., Ltd is the lead sponsor of 21 studies on the registry; 10 are open to participants now.
3 of the studies in Obesity by Shanghai Minwei Biotechnology Co., Ltd that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07778693Phase 3Shanghai Minwei Biotechnology Co., LtdPhase 3 Study of MWN109 Injection in Participants With Overweight or Obesity | 2027-09 |
| NCT07779980Shanghai Minwei Biotechnology Co., LtdPhase 1 Clinical Study of MWN110 Injection in Healthy Participants and Overweight or Obese Participants | 2027-08 |
| NCT07824804Shanghai Minwei Biotechnology Co., LtdPhase 1 Clinical Study of MWN117 Injection in Healthy Participants and Participants With Obesity | 2027-09 |
Among the 14 studies in Obesity by Shanghai Minwei Biotechnology Co., Ltd, from their registry updates:
Nothing recorded among them since 2026-09-25.
This study is a randomized, double-blind, placebo-controlled, single-dose and multiple-dose, dose-escalation phase I clinical trial, aiming to evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic characteristics, and immunogenicity of MWN105 injection in healthy Chinese volunteers, and to provide a reference for the next clinical trial.
This study includes a single ascending dose (SAD) study and a multiple ascending dose (MAD) study. The SAD study consists of 4 dose groups; the MAD study consists of 2 dose groups and adopts a 4-week dose titration scheme.
The study plans to enroll 55 volunteers. The primary endpoint is the incidence of adverse events. The secondary endpoints are the pharmacokinetic and pharmacodynamic characteristics and immunogenicity endpoints.
11,522 studies on the registry are indexed under Obesity; 2,033 are open to participants now.
This study's enrollment of 55 is below the median of 67 across 9,006 interventional studies indexed under Obesity.
Browse Obesity studies →Shanghai Minwei Biotechnology Co., Ltd is the lead sponsor of 21 studies on the registry; 10 are open to participants now.
First submitted after Shanghai Minwei Biotechnology Co., Ltd became part of Lepu Medical.
Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MWN105 S consists of 4 dose groups, with doses ranging from 3 mg to 30 mg. Healthy participants in all dose groups were randomly assigned to receive a single subcutaneous dose of MWN105 or placebo.
Drug: MWN105 · Drug: Placebo
MWN105 Cohort M consists of 2 dose groups. In all dose groups, Healthy participants are randomized to receive 4 subcutaneous doses of MWN105 or placebo, administered once weekly.
Drug: MWN105 · Drug: Placebo
Incidence of adverse events (AEs)
The incidence of adverse events (AEs) and serious adverse events (SAEs).
Time frame: From Day 1 to Day 50
Maximum Concentration (Cmax)
Cmax of MWN105.
Time frame: From Day 1 to Day 29
Time to Reach Maximum Concentration (Tmax)
Tmax of MWN105.
Time frame: From Day 1 to Day 29
Area Under the Curve From Time 0 to Last Quantifiable Time Point (AUC0-t)
AUC0-t of MWN105.
Time frame: From Day 1 to Day 29
Area Under the Curve From Time 0 to Infinity (AUC0-inf)
AUC0-inf of MWN105.
Time frame: From Day 1 to Day 29
Elimination Half-Life (t1/2)
t1/2 of MWN105.
Time frame: From Day 1 to Day 29
Steady State Maximum Concentration (Cmax,ss)
Cmax,ss of MWN105.
Time frame: From Day 1 to Day 50
Time to Reach Maximum Concentration at Steady State (Tmax,ss)
Tmax,ss of MWN105.
Time frame: From Day 1 to Day 50
Steady State Area Under the Curve From Time 0 to Last Quantifiable Time Point (AUC0-t,ss)
AUC0-t,ss of MWN105.
Time frame: From Day 1 to Day 50
Steady State Area Under the Curve from time zero to infinity (AUC0-inf,ss)
AUC0-inf,ss of MWN105.
Time frame: From Day 1 to Day 50
Steady State Apparent Terminal Elimination Half-life (t1/2,ss)
t1/2,ss of MWN105.
Time frame: rom Day 1 to Day 50
Change from baseline in body weight over time
Time frame: Baseline, Day 29, Day 50
Change from baseline in body mass index (BMI) over time
Time frame: Baseline, Day 29, Day 50
Change from baseline in waist circumference over time
Time frame: Baseline, Day 29, Day 50
Change from baseline in hip circumference over time
Time frame: Baseline, Day 29, Day 50
Change from baseline in waist-to-hip ratio over time
Time frame: Baseline, Day 29, Day 50
Change from baseline in fasting blood glucose over time
Time frame: Baseline, Day 29, Day 50
Change from baseline in C-peptide over time
Time frame: Baseline, Day 29, Day 50
Detect anti-drug antibodies (ADA) and their titers
Time frame: Baseline, Day 29, Day 50
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: MWN105
Shanghai Minwei Biotechnology Co., Ltd →